Supplementary Materials

Supplementary Material for:

PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis

Audrey S. Dickey, Dafne N. Sanchez, Martin Arreola, Kunal R. Sampat, Weiwei Fan, Nicolas Arbez, Sergey Akimov, Michael J. Van Kanegan, Kohta Ohnishi, Stephen K. Gilmore-Hall, April L. Flores, Janice M. Nguyen, Nicole Lomas, Cynthia L. Hsu, Donald C. Lo, Christopher A. Ross, Eliezer Masliah, Ronald M. Evans, Albert R. La Spada*

*Corresponding author. Email: alaspada{at}ucsd.edu

Published 6 December 2017, Sci. Transl. Med. 9, eaal2332 (2017)
DOI: 10.1126/scitranslmed.aal2332

This PDF file includes:

  • Fig. S1. Bexarotene promotes neuroprotection by activating PPARδ.
  • Fig. S2. Bexarotene pharmacodynamics analysis of PPARδ target gene activation in CNS yields a suitable dosage and delivery scheme for preclinical trial testing.
  • Fig. S3. Bexarotene treatment of HD mice ameliorates motor function decline.
  • Fig. S4. Bexarotene promotes PPARδ activation of target genes in skeletal muscle after 1 week of treatment.
  • Fig. S5. PPARδ activation enhances oxidative function in neurons and restores an oxidative gene expression pattern in the CNS of HD mice.
  • Fig. S6. Bexarotene-mediated htt protein aggregate reduction is RXR-dependent.
  • Fig. S7. PPARδ activation of autophagy does not require TFEB.

[Download PDF]